These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19146900)

  • 1. Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise.
    Fruth U
    Vaccine; 2009 Mar; 27(14):1989-96. PubMed ID: 19146900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.
    Rida W; Fast P; Hoff R; Fleming T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):195-203. PubMed ID: 9390572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.
    Follmann D; Duerr A; Tabet S; Gilbert P; Moodie Z; Fast P; Cardinali M; Self S
    J Acquir Immune Defic Syndr; 2007 Jan; 44(1):49-60. PubMed ID: 17075387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 7. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 8. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
    Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
    J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Executive summary and recommendations from WHO/UNAIDS and AAVP consultation on: 'The inclusion of adolescents in HIV vaccine trials', 16-18 March 2006 in Gaborone, Botswana.
    ; Osmanov S
    AIDS; 2007 Sep; 21(14):W1-10. PubMed ID: 17721089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002.
    Chang ML; Vitek C; Esparza J;
    AIDS; 2003 Oct; 17(15):W1-10. PubMed ID: 14523295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
    Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
    Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group
    AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some statistical issues in HIV vaccine trials.
    Rida WN; Lawrence DN
    Stat Med; 1994 Oct 15-30; 13(19-20):2155-77. PubMed ID: 7846417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.
    Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD
    Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
    Wick WD; Gilbert PB; Self SG
    PLoS Comput Biol; 2006 Jun; 2(6):e64. PubMed ID: 16789816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.